JP2023513658A5 - - Google Patents

Info

Publication number
JP2023513658A5
JP2023513658A5 JP2022531616A JP2022531616A JP2023513658A5 JP 2023513658 A5 JP2023513658 A5 JP 2023513658A5 JP 2022531616 A JP2022531616 A JP 2022531616A JP 2022531616 A JP2022531616 A JP 2022531616A JP 2023513658 A5 JP2023513658 A5 JP 2023513658A5
Authority
JP
Japan
Application number
JP2022531616A
Other languages
Japanese (ja)
Other versions
JP2023513658A (ja
JP7691421B2 (ja
JPWO2021113524A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063130 external-priority patent/WO2021113524A2/en
Publication of JP2023513658A publication Critical patent/JP2023513658A/ja
Publication of JP2023513658A5 publication Critical patent/JP2023513658A5/ja
Publication of JPWO2021113524A5 publication Critical patent/JPWO2021113524A5/ja
Application granted granted Critical
Publication of JP7691421B2 publication Critical patent/JP7691421B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022531616A 2019-12-04 2020-12-03 Glp2受容体アゴニストおよびその使用方法 Active JP7691421B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962943667P 2019-12-04 2019-12-04
US62/943,667 2019-12-04
US202062994791P 2020-03-25 2020-03-25
US62/994,791 2020-03-25
PCT/US2020/063130 WO2021113524A2 (en) 2019-12-04 2020-12-03 Glp2 receptor agonists and methods of use

Publications (4)

Publication Number Publication Date
JP2023513658A JP2023513658A (ja) 2023-04-03
JP2023513658A5 true JP2023513658A5 (https=) 2023-12-12
JPWO2021113524A5 JPWO2021113524A5 (https=) 2023-12-12
JP7691421B2 JP7691421B2 (ja) 2025-06-11

Family

ID=76222285

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022531616A Active JP7691421B2 (ja) 2019-12-04 2020-12-03 Glp2受容体アゴニストおよびその使用方法
JP2022532862A Active JP7834640B2 (ja) 2019-12-04 2020-12-03 ペプチドコンジュゲートおよび使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022532862A Active JP7834640B2 (ja) 2019-12-04 2020-12-03 ペプチドコンジュゲートおよび使用方法

Country Status (10)

Country Link
US (2) US12583900B2 (https=)
EP (2) EP4069274A4 (https=)
JP (2) JP7691421B2 (https=)
KR (2) KR20220110244A (https=)
CN (2) CN115052886B (https=)
AU (2) AU2020397917A1 (https=)
CA (2) CA3163522A1 (https=)
IL (2) IL293460A (https=)
MX (2) MX2022006861A (https=)
WO (2) WO2021113535A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014364589B2 (en) 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
AU2020397917A1 (en) 2019-12-04 2022-06-23 The Scripps Research Institute GLP2 receptor agonists and methods of use
MX2023014771A (es) 2021-06-09 2024-03-19 Scripps Research Inst Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.
WO2023207106A1 (zh) * 2022-04-29 2023-11-02 苏州星洲生物科技有限公司 Glp-1/gip受体共激动剂、包含其的药物组合物及其用途
CN114949183B (zh) * 2022-05-07 2023-02-28 山东京卫制药有限公司 一种替尔泊肽粉雾剂及其制备方法
TW202410918A (zh) * 2022-05-27 2024-03-16 韓商D&D製藥科技股份有限公司 用於治療神經病症之組合物及方法
CR20250247A (es) * 2022-12-21 2025-08-18 Boehringer Ingelheim Int Agonistas triples de los receptores de glp1/gip/npy2
CN117586374B (zh) * 2023-10-07 2024-11-29 深圳湾实验室 Glp-1r/gipr/gcgr三重激动剂类似物及其用途
WO2025184552A2 (en) * 2024-03-01 2025-09-04 The Scripps Research Institute Dual gip/glp-1 peptide conjugates and methods of use
WO2025217640A1 (en) * 2024-04-12 2025-10-16 Eli Lilly And Company Compositions and methods for treating metabolic diseases

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
WO1994012158A1 (en) 1992-12-02 1994-06-09 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
EP0707650B1 (en) 1993-06-21 2003-05-21 Genentech, Inc. Process for producing human relaxin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
CZ287945B6 (cs) 1993-09-17 2001-03-14 Novo Nordisk A/S Inzulinový derivát a farmaceutický prostředek s jeho obsahem pro léčení diabetu
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
DK0779806T3 (da) 1994-09-09 2000-11-27 Takeda Chemical Industries Ltd Præparat til forsinket frigivelse indeholdende et metalsalt af et peptid
ATE212545T1 (de) 1995-03-28 2002-02-15 Fidia Advanced Biopolymers Srl Nanosphären mit einem biokompatiblen polysaccharid
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
TW457240B (en) 1995-04-20 2001-10-01 Janssen Pharmaceutica Nv Novel triazolones as apolipoprotein-B synthesis inhibitors
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
NZ310644A (en) 1995-06-07 1999-08-30 Alkermes Inc Composition for sustained release of human growth hormone
US5911997A (en) 1995-06-07 1999-06-15 Connetics Corporation Relaxin-like factor and methods and uses thereof
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5612051A (en) 1995-11-17 1997-03-18 Yue; Samuel K. Method of treating involuntary muscle dysfunction with relaxin hormone
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
DE19822820A1 (de) 1998-05-20 1999-11-25 Biotechnolog Forschung Gmbh Pharmazeutisches Präparat zur Wundbehandlung
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
JP2004535401A (ja) 2001-05-21 2004-11-25 ネクター セラピューティックス 化学的に改変されたインスリンの肺投与
EP1572720A4 (en) 2002-05-24 2008-12-24 Nps Allelix Corp PROCESS FOR THE ENZYMATIC PRODUCTION OF GLP-2 (1-34) AND GLP-2 (1-33) PEPTIDES
AU2003239478A1 (en) * 2002-06-04 2003-12-22 Eli Lilly And Company Modified glucagon-like peptide-1 analogs
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
WO2004100997A2 (en) 2003-05-12 2004-11-25 Affymax, Inc. Spacer moiety for poly(ethylene glycol) -modified peptides
US20060183667A1 (en) 2003-07-11 2006-08-17 Novo Nordisk A/S Stabilised insulin compositions
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 glp-1 유도체
WO2005118620A2 (en) 2004-05-27 2005-12-15 New York University Methods for preparing internally constraied peptides and peptidomimetics
WO2006066258A2 (en) 2004-12-17 2006-06-22 Neose Technologies, Inc. Lipoconjugation of peptides
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
DE602006020123D1 (de) 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
WO2007067828A2 (en) 2005-10-24 2007-06-14 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
CN101389648B (zh) 2006-02-22 2013-07-17 默沙东公司 肽胃泌酸调节素衍生物
US20080305519A1 (en) 2006-02-23 2008-12-11 Qing Lin Biochemical method for specific protein labeling
KR20080113226A (ko) 2006-03-16 2008-12-29 더 스크립스 리서치 인스티튜트 비천연 아미노산 페닐셀레노시스테인을 함유하는 단백질의 유전자적으로 프로그램된 발현
KR20090005329A (ko) 2006-03-20 2009-01-13 머크 앤드 캄파니 인코포레이티드 뉴로메딘 u 수용체 효능제 및 이의 용도
WO2007109354A2 (en) 2006-03-21 2007-09-27 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
ES2495741T3 (es) 2006-04-20 2014-09-17 Amgen, Inc Compuestos de GLP-1
AU2007267833B2 (en) 2006-05-26 2012-07-26 Amylin Pharmaceuticals, Llc Composition and methods for treatment of congestive heart failure
WO2008028117A2 (en) 2006-08-31 2008-03-06 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
EP2069502B1 (en) 2006-09-27 2014-02-26 Novo Nordisk A/S Method for making maturated insulin polypeptides
KR20090091145A (ko) 2006-10-27 2009-08-26 웨이-치앙 션 지질화된 인터페론 및 이의 용도
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CN105061577A (zh) 2006-12-14 2015-11-18 爱勒让治疗公司 双巯基大环化系统
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
ES2398310T3 (es) 2007-02-23 2013-03-15 Aileron Therapeutics, Inc. Péptidos macrocíclicos unidos a triazol
US8420598B2 (en) 2007-04-20 2013-04-16 B & L Delipharm Corp. Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
AU2008266753A1 (en) 2007-06-20 2008-12-24 Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. ApoA-1 peptide mimetics
KR20100126361A (ko) 2008-02-08 2010-12-01 에일러론 테라퓨틱스 인코포레이티드 치료용 펩티드유사 거대고리
WO2009126292A2 (en) 2008-04-08 2009-10-15 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
US20110144303A1 (en) 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
DK2300035T3 (en) 2008-06-17 2015-11-16 Univ Indiana Res & Tech Corp Mixed GIP-based agonists for the treatment of metabolic diseases and obesity
US8586707B2 (en) 2008-09-16 2013-11-19 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
ES2666458T3 (es) 2008-09-22 2018-05-04 Aileron Therapeutics, Inc. Macrociclos peptidomiméticos
CN102203126A (zh) 2008-09-22 2011-09-28 爱勒让治疗公司 用于制备纯化的多肽组合物的方法
CN102884074A (zh) 2008-09-22 2013-01-16 爱勒让治疗公司 拟肽大环化合物
EP2352507A4 (en) 2008-11-24 2012-04-25 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES
WO2010083347A2 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
MX2012003939A (es) 2009-09-30 2012-07-30 Glaxo Group Ltd Fusiones y conjugados de farmaco.
US20110223149A1 (en) 2009-10-14 2011-09-15 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2512518A1 (en) 2009-12-16 2012-10-24 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US20110243943A1 (en) 2010-04-02 2011-10-06 Athena Discovery, Inc. Treatment using relaxin-fusion proteins with extended in vivo half-lives
JP2013532172A (ja) * 2010-07-09 2013-08-15 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド 安定化したインスリン分泌促進ペプチド及び使用方法
BR112013000603A2 (pt) 2010-07-09 2016-07-05 Jv Bio Srl anticorpos conjugados com lipídios
WO2012012352A2 (en) 2010-07-19 2012-01-26 Amidebio, Llc Modified peptides and proteins
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
MA34521B1 (fr) 2010-08-17 2013-09-02 Ambrx Inc Polypeptides de relaxine modifiés et leurs utilisations
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US9029332B2 (en) 2010-12-15 2015-05-12 The Research Foundation For The State University Of New York Cross-linked peptides and proteins, methods of making same, and uses thereof
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
SG191252A1 (en) 2010-12-22 2013-07-31 Marcadia Biotech Inc Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
CA2834657A1 (en) 2011-04-29 2012-11-01 Kinemed, Inc. Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
EP2726502A1 (en) 2011-07-01 2014-05-07 Bayer Intellectual Property GmbH Relaxin fusion polypeptides and uses thereof
JP2014529293A (ja) 2011-07-08 2014-11-06 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH レラキシンを放出する融合タンパク質およびその使用
AR088392A1 (es) 2011-10-18 2014-05-28 Aileron Therapeutics Inc Macrociclos peptidomimeticos
KR101895047B1 (ko) 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN117462693A (zh) 2012-02-27 2024-01-30 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
SG11201508469YA (en) * 2013-05-02 2015-11-27 Glaxosmithkline Ip Dev Ltd Therapeutic peptides
EP3019531A4 (en) 2013-07-11 2017-03-15 The California Institute for Biomedical Research Immunoglobulin fusion proteins and compositions thereof
CN105792851B (zh) * 2013-09-13 2023-10-10 斯克利普斯研究所 修饰的治疗剂及其组合物
AU2014364589B2 (en) * 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
JO3575B1 (ar) 2015-01-09 2020-07-05 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
MA41794A (fr) 2015-03-18 2018-01-23 The California Institute For Biomedical Res Agents thérapeutiques modifiés et compositions associées
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017024318A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
WO2017024317A2 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
WO2017210600A1 (en) 2016-06-03 2017-12-07 The Scripps Research Institute Compositions and methods of modulating immune response
JOP20190095A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
CN117510491A (zh) 2016-12-23 2024-02-06 阿尔维纳斯运营股份有限公司 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
EP3580212A4 (en) 2017-02-08 2021-03-17 Dana Farber Cancer Institute, Inc. REGULATION OF CHEMERIC ANTIGEN RECEPTORS
AU2018219292B2 (en) 2017-02-08 2024-09-26 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation with heterobifunctional compounds
AU2018248417A1 (en) 2017-04-05 2019-11-14 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
US11802132B2 (en) 2018-02-23 2023-10-31 Dana-Farber Cancer Institute, Inc. Small molecules for inducing selective protein degradation and uses thereof
WO2019203645A1 (en) * 2018-04-19 2019-10-24 Stichting Vu Protein macrocyclization
TWI847981B (zh) * 2018-04-25 2024-07-11 比利時商健生藥品公司 類升糖素肽1 (glp-1)融合肽偶合環狀酪酪肽接合物及其用途
CN112469731B (zh) 2018-07-23 2024-11-29 伊莱利利公司 Gip/glp1共激动剂化合物
EP3864030A4 (en) 2018-10-12 2022-09-21 The Scripps Research Institute Compounds and methods for dcaf-mediated protein degradation
AU2020397917A1 (en) * 2019-12-04 2022-06-23 The Scripps Research Institute GLP2 receptor agonists and methods of use
MX2023014771A (es) 2021-06-09 2024-03-19 Scripps Research Inst Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.

Similar Documents

Publication Publication Date Title
JP2023513658A5 (https=)
JP2023504184A5 (https=)
JPWO2022024756A1 (https=)
BR102021015500A2 (https=)
CN305588018S (https=)
CN305531497S (https=)
CN305532574S (https=)
CN305533470S (https=)
CN305532541S (https=)
CN305531301S (https=)
CN305531863S (https=)
CN305531302S (https=)
CN305530558S (https=)
CN305534153S (https=)
CN305527883S (https=)
CN305534807S (https=)
CN305527036S (https=)
CN305562382S (https=)
CN305566084S (https=)
CN305581291S (https=)
CN305603001S (https=)
CN305601643S (https=)
CN305589130S (https=)
CN305535806S (https=)
CN305564632S (https=)